Down-Titration of Infliximab:The Real-Life Use in Psoriatic Patients

December 2016 | Volume 15 | Issue 12 | Editorials | 1584 | Copyright © December 2016


Federico Bardazzi MD,a Camilla Loi MD,a Francesca Prignano MD,b Federica Ricceri MD,b Ferdinando Giordano PhD,c Annalisa Patrizi MD,a and Michela Magnano MDa

aDepartment of Specialized, Clinical and Experimental Medicine, Division of Dermatology, University of Bologna, Italy bDepartment of Medical-Surgical Critical Area, Section of Clinical, Preventive and Oncological Dermatology, University of Florence, Italy cDepartment of Physics, University of Catania and INFN, Italy

be considered an alternative method for patients with low disease activity, reducing the costs of the therapy and, more importantly, improving significantly their quality of life.

Disclosure

The authors have no conflict of interest to disclose.

References

  1. Sengupta S, Ray J, Ghosh B. Quality of Life and Clinical Response to On-Demand Maintenance Doses of Infliximab in Patients With Ankylosing Spondylitis. J Clin Rheumatol. 2015 Oct;21(7):355-8. 
  2. Van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JWJ, van Vollenhoven RF, van den Bemt BJF. Down-titration and discontinu- ation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity (Review). Cochrane Database Syst Rev. 2014 Sep 29: CD010455. 
  3. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7(4):e33486. 
  4. Mörck B, Pullerits R, Geijer M, Bremell T, Forsblad-d’Elia H. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediators Inflamm. 2013; 2013: 289845. 
  5. Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, Brou- wer E, Spoorenberg A. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):174-80. 
  6. Callis Duf n K, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, Shin DB, Van Voorhees AS, Gelfand JM. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014 Mar;170(3):672-80. 
  7. Piaserico S, Gisondi P, DeSimone C, Marinello E, Conti A, Amerio P, Peserico A. Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. Acta Derm Venereol. 2015 Aug 13. 

AUTHOR CORRESPONDENCE

Michela Magnano MD michela.magnano@gmail.com